At the training lane, a casualty with a painful leg injury is awake and answering questions. The medic has several analgesic options. The first decision is not which vial to open. It is whether the casualty can stay in the fight, and what level of pain control will preserve safe function.
The 2026 Tactical Combat Casualty Care (TCCC) Guidelines, dated 1 May 2026, change the battlefield analgesia framework. The new two-step approach organizes initial treatment around mission capability, adds suzetrigine to the Combat Wound Medication Pack, and pairs the pack with ketamine or esketamine for a casualty who cannot stay in the fight (TCCC Guidelines, 1 May 2026; Barbee et al., TCCC Guideline Change 25-03).
The May 2026 TCCC edition replaces the earlier multi-option analgesia approach with a simpler two-step model: a non-opioid medication pack for a casualty who can stay in the fight, and an added provider-administered option for a casualty who cannot (TCCC Guidelines, 1 May 2026; Barbee et al.). The guideline change paper says CoTCCC began the review after loss of access to oral transmucosal fentanyl citrate and amid planning for large-scale combat operations; the authors describe the update as a way to simplify logistics and reduce provider cognitive burden (JSOM article page).
This changes the decision prompt: assess the injury, then ask whether the casualty can remain mission-capable, rather than relying chiefly on pain severity plus a separate shock-risk branch (Barbee et al.). That may be easier to teach under pressure, but it does not remove judgment or reassessment.
The guideline's explicit goal is tolerable pain while preserving airway patency, respiratory drive, and mentation—not complete relief or total sedation (TCCC Guidelines, 1 May 2026). A quiet casualty is not automatically a safely treated casualty.
For a casualty who can stay in the fight, the TCCC Combat Wound Medication Pack includes acetaminophen, meloxicam, and suzetrigine. The guideline lists acetaminophen 1,000–1,300 mg by mouth every eight hours, meloxicam 15 mg by mouth once daily, and suzetrigine 100 mg once followed by 50 mg every 12 hours (TCCC Guidelines, 1 May 2026). It says the casualty may self-administer or receive co-administration from TCCC personnel.
If the casualty cannot stay in the fight, the guideline directs TCCC personnel to have the casualty take the medication pack if it has not already been taken, then use one of the listed ketamine or esketamine options (TCCC Guidelines, 1 May 2026). The specified ketamine options are 100 mg intramuscularly, 50 mg intranasally, or 25 mg (or 0.2–0.3 mg/kg) by slow IV/IO push over one minute; the esketamine option is 14 mg or 28 mg intranasally. The guideline lists repeat doses every 30 minutes as needed, with reduction in pain or nystagmus as endpoints (TCCC Guidelines, 1 May 2026).
These doses summarize the guideline; follow the current official document, medical direction, and scope of practice. The guideline calls for AVPU documentation before ketamine, close airway, breathing, and circulation monitoring after potent analgesics, and disarming a casualty who receives ketamine (TCCC Guidelines, 1 May 2026). TBI or eye injury alone does not rule out ketamine, but sedating analgesics can complicate neurologic assessment (TCCC Guidelines, 1 May 2026).
Suzetrigine is the most visible new medication in the mission-capable pathway. The U.S. Food and Drug Administration approved it in January 2025 for moderate-to-severe acute pain in adults (FDA approval announcement). The FDA describes two controlled efficacy trials in acute surgical pain after abdominoplasty and bunionectomy, plus an open-label safety study involving a wider range of acute pain conditions (FDA approval announcement; FDA Drug Trials Snapshot).
The FDA evidence supports approved adult acute-pain use, but it does not answer every question about combat wounds or evacuation. The TCCC paper describes a guideline review; the FDA summary describes clinical trial populations, so the sources answer different questions (Barbee et al.; FDA Drug Trials Snapshot). Medics should know both the new doctrinal place of the drug and the limits of claims about field effectiveness.
The other big change is the structure around ketamine and esketamine. The updated guideline gives a simplified set of routes and fixed doses for a casualty who cannot stay in the fight, and a monitoring goal that keeps airway, breathing, and mentation in view (TCCC Guidelines, 1 May 2026; Barbee et al.). It is not a cue to stack medications until the casualty is quiet. The guideline says to avoid co-administering benzodiazepines with ketamine or esketamine and warns against polypharmacy (TCCC Guidelines, 1 May 2026).
Teach the new algorithm as a short verbal sequence: Can the casualty stay in the fight? Has the medication pack been taken? If not mission-capable, which guideline option is within my role and available now? What will I monitor next? The 2026 guideline's mission-capable split and its explicit preservation targets give instructors a useful structure for those repetitions (TCCC Guidelines, 1 May 2026).
Then change the case. A casualty who could answer questions may become less able to perform the mission. A casualty who received a potent analgesic needs continued monitoring. Ask the learner to say what changed, repeat the mental-status check when indicated, and hand over the medication and reassessment details to the next team. The guideline requires close airway, breathing, and circulation monitoring after potent analgesia and documentation of AVPU before ketamine (TCCC Guidelines, 1 May 2026).
Use a branching scenario to make the trainee defend the choice, not recite a dose in isolation. The free MilMedSim scenario is one way to rehearse decisions. For the broader training ecosystem, see Global MedOps Command.
I have spent more than 25 years in emergency medicine, and I have watched pain control go wrong in both directions. We have left patients hurting because we feared medication. We have also treated the number on the pain scale and missed the patient in front of us. The 2026 TCCC change gets the central question right: can this casualty stay in the fight, and what will let that person function safely? A medication algorithm is only useful when it gives the medic a decision that survives noise and stress. In HEMS, a patient who could answer at pickup may be harder to assess when the team is moving and the aircraft is loud. In the Guard, care passes from one set of hands to another. The plan has to travel with the patient.
That being said, suzetrigine is a new tool in a very old problem. The FDA evidence described in the approval summary is acute-pain evidence, largely from surgical settings, not proof that the drug solves every battlefield pain problem (FDA approval summary). I want medics to know what changed in the guideline and to be honest about what the studies can and cannot tell us. The guideline's stated goal is tolerable pain with airway, respiratory drive, and mentation preserved; that is a better target than chasing a zero (TCCC Guidelines, 1 May 2026). A dose on a card does not tell you whether the casualty can follow a command, keep an airway open, or take part in the next decision. Those findings matter as much as the initial complaint.
If you are the medic on the ground, practice saying your decision out loud: mission-capable or not, medication given or not, and what you will reassess. If you are a medical officer, teach the team to recognize when the casualty no longer fits the first branch. Make the trainee explain what would change the plan, then make that change happen in the scenario. Carry the medication name, dose, route, time, response, and next check into the handoff. Repeat the scenario with a new distraction or a change in the casualty's status. The team should hear the reason for the plan, since medication choices can change as the casualty's status changes (TCCC Guidelines, 1 May 2026). That explanation builds judgment, not just recall. Good pain care is a decision you keep checking.
The 1 May 2026 TCCC Guidelines use a two-step framework based on whether the casualty can stay in the fight. The medication pack adds suzetrigine, and the non-mission-capable pathway lists ketamine or intranasal esketamine options (TCCC Guidelines; Barbee et al.).
The FDA approved suzetrigine for moderate-to-severe acute pain in adults. Its public summary describes controlled studies in surgical pain and an open-label safety study across a broader range of acute pain conditions; those sources do not establish a combat-wound-specific indication (FDA approval announcement; FDA Drug Trials Snapshot).
The guideline calls for tolerable pain while preserving airway patency, respiratory drive, and mentation, rather than complete pain elimination or total sedation (TCCC Guidelines).
If you're a combat medic, corpsman, flight medic, or any provider treating casualties in the field trying to understand how AI will actually impact your clinical practice — not just the hype — I put together a free practical guide. You can download it here: AI in EM Survival Guide.